STAT+：ESMO 周末过后值得关注的五项生物科技进展
STAT+: Five biotech updates to read after ESMO this weekend
Moderna CEO Stéphane Bancel 在 ESMO 上表示，个体化癌症疫苗 intismeran 在关键 III 期试验成功后，公司与 Merck 正加紧向 FDA 提交上市申请，他预计 2027 年获批。两家公司还准备在其他癌症中大力测试该疫苗。
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Soundtrack at present: Iggy Pop, The Idiot.
Moderna CEO sees vaccine possibility beyond melanoma
Moderna CEO Stéphane Bancel is looking well beyond melanoma after the company’s personalized cancer vaccine, intismeran, succeeded in a pivotal Phase 3 trial. In an interview with STAT at the ESMO meeting in Madrid, Bancel said Moderna and partner Merck are racing to submit the vaccine for FDA approval, which he expects in 2027. The companies, he said, are also preparing to test it aggressively in other cancers.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com